CEO of Novo Nordisk blames insurers and middlemen for high costs of weight-loss drugs in the U.S.

The high costs of weight-loss drugs in the U.S. have come under scrutiny, with the chief executive of Novo Nordisk, the company behind popular medications like Ozempic and Wegovy, pointing the finger at insurers and middlemen during a recent congressional testimony.

Lars Fruergaard Jørgensen, the CEO of Novo Nordisk, emphasized that his company does not set the prices for patients, placing the responsibility on insurance companies instead. This revelation comes as concerns mount over the affordability of these crucial medications, with Sen. Bernie Sanders warning that high drug costs could strain Medicare and drive up insurance premiums.

Ozempic and Wegovy have become go-to treatments for diabetes, obesity, and heart disease, but access to these drugs has been found to be unequal. A recent study revealed that patients on Medicare and Medicaid may face greater barriers to obtaining these medications compared to those with private insurance.

In response to pressure from lawmakers, Jørgensen expressed willingness to work towards reducing prices and increasing access to these drugs. Sanders highlighted the stark price disparities between the U.S. and other countries, with Americans paying significantly more for these medications.

As the debate over drug pricing continues, the focus remains on ensuring equitable access to essential medications like Ozempic and Wegovy. Stay tuned for further developments on this critical issue.